FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3082087942> ?p ?o ?g. }

• W3082087942 endingPage "205435812094829" @default.
• W3082087942 startingPage "205435812094829" @default.
• W3082087942 abstract "Background: Recent years have witnessed an encouraging expansion of knowledge and management tools in the care of patients with autosomal dominant polycystic kidney disease (ADPKD), including measurement of total kidney volume as a biomarker of disease progression, stringent blood pressure targets to slow cyst growth, and targeted treatments such as tolvaptan. Objectives: We sought to evaluate clinicians’ familiarity with, and usage of, novel evidence-based management tools for ADPKD. Design: On-line survey. Setting: British Columbia, Canada. Participants: Nephrologists in academic and community practice (excluding clinicians who practice exclusively in transplantation). Measurements: Participants answered multiple-choice questions in 6 domains: sources of information, self-identified needs for optimal care delivery, prognostication, imaging tests, blood pressure targets, and use of tolvaptan. Methods: An online survey was developed and disseminated via email to 65 nephrologists engaged in current clinical practice in British Columbia. Results: A total of 29 nephrologists (45%) completed the questionnaire. The most popular source of information was the primary literature (83% of respondents). While 86% of respondents reported assessing the risk of disease progression before the onset of kidney function decline, most were using traditional metrics such as blood pressure and proteinuria rather than validated prediction tools such as the Mayo Classification. Although 90% of respondents obtained additional imaging after diagnosis in some or all of their ADPKD patients, only 1 in 5 reported being confident in their ability to interpret kidney size. The recommended blood pressure (BP) target of <110/75 mmHg was sought by 17% of respondents. All respondents reported being familiar with the literature regarding tolvaptan; however, only half were confident in their ability to identify suitable patients for treatment. The top 3 needs identified by clinicians were better access to medications (69%), clear management protocols (66%), and easier access to imaging tests (59%). Limitations: Funding mechanisms for tolvaptan can vary; therefore, clinicians’ experience with the drug may not be generalizable. Although the response rate was acceptable, the survey is nonetheless subject to responder bias. Conclusion: This survey indicates that there is substantial variability in the usage of, and familiarity with, evidence-based ADPKD management tools among contemporary nephrologists, contributing to incomplete translation of evidence into clinical practice. Providing greater access to tolvaptan or imaging tests is unlikely to improve patient care without enhancing knowledge translation and education. Trial Registration: Not applicable as this was a survey." @default.
• W3082087942 created "2020-09-08" @default.
• W3082087942 creator A5044179329 @default.
• W3082087942 creator A5046130400 @default.
• W3082087942 creator A5056281880 @default.
• W3082087942 creator A5085325427 @default.
• W3082087942 date "2020-01-01" @default.
• W3082087942 modified "2023-10-12" @default.
• W3082087942 title "A Provincial Survey of the Contemporary Management of Autosomal Dominant Polycystic Kidney Disease" @default.
• W3082087942 cites W1963623990 @default.
• W3082087942 cites W1966416547 @default.
• W3082087942 cites W1987246427 @default.
• W3082087942 cites W1989597713 @default.
• W3082087942 cites W1997286719 @default.
• W3082087942 cites W1999560996 @default.
• W3082087942 cites W2081753990 @default.
• W3082087942 cites W2093911127 @default.
• W3082087942 cites W2101067234 @default.
• W3082087942 cites W2112604521 @default.
• W3082087942 cites W2112643254 @default.
• W3082087942 cites W2115735438 @default.
• W3082087942 cites W2116811919 @default.
• W3082087942 cites W2142149055 @default.
• W3082087942 cites W2142590599 @default.
• W3082087942 cites W2143108257 @default.
• W3082087942 cites W2143205720 @default.
• W3082087942 cites W2156488542 @default.
• W3082087942 cites W2156813589 @default.
• W3082087942 cites W2203078370 @default.
• W3082087942 cites W2412010777 @default.
• W3082087942 cites W2586813559 @default.
• W3082087942 cites W2592253867 @default.
• W3082087942 cites W2739908263 @default.
• W3082087942 cites W2760905693 @default.
• W3082087942 cites W2765795120 @default.
• W3082087942 cites W2779250159 @default.
• W3082087942 cites W2800737974 @default.
• W3082087942 cites W2883353278 @default.
• W3082087942 cites W4211207317 @default.
• W3082087942 cites W68056817 @default.
• W3082087942 doi "https://doi.org/10.1177/2054358120948294" @default.
• W3082087942 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7476332" @default.
• W3082087942 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32953126" @default.
• W3082087942 hasPublicationYear "2020" @default.
• W3082087942 type Work @default.
• W3082087942 sameAs 3082087942 @default.
• W3082087942 citedByCount "2" @default.
• W3082087942 countsByYear W30820879422021 @default.
• W3082087942 countsByYear W30820879422022 @default.
• W3082087942 crossrefType "journal-article" @default.
• W3082087942 hasAuthorship W3082087942A5044179329 @default.
• W3082087942 hasAuthorship W3082087942A5046130400 @default.
• W3082087942 hasAuthorship W3082087942A5056281880 @default.
• W3082087942 hasAuthorship W3082087942A5085325427 @default.
• W3082087942 hasBestOaLocation W30820879421 @default.
• W3082087942 hasConcept C126322002 @default.
• W3082087942 hasConcept C159641895 @default.
• W3082087942 hasConcept C177713679 @default.
• W3082087942 hasConcept C2776266639 @default.
• W3082087942 hasConcept C2778198053 @default.
• W3082087942 hasConcept C2778653478 @default.
• W3082087942 hasConcept C2779134260 @default.
• W3082087942 hasConcept C2779561371 @default.
• W3082087942 hasConcept C2780091579 @default.
• W3082087942 hasConcept C2780145431 @default.
• W3082087942 hasConcept C2780615674 @default.
• W3082087942 hasConcept C512399662 @default.
• W3082087942 hasConcept C54847362 @default.
• W3082087942 hasConcept C71924100 @default.
• W3082087942 hasConcept C84393581 @default.
• W3082087942 hasConceptScore W3082087942C126322002 @default.
• W3082087942 hasConceptScore W3082087942C159641895 @default.
• W3082087942 hasConceptScore W3082087942C177713679 @default.
• W3082087942 hasConceptScore W3082087942C2776266639 @default.
• W3082087942 hasConceptScore W3082087942C2778198053 @default.
• W3082087942 hasConceptScore W3082087942C2778653478 @default.
• W3082087942 hasConceptScore W3082087942C2779134260 @default.
• W3082087942 hasConceptScore W3082087942C2779561371 @default.
• W3082087942 hasConceptScore W3082087942C2780091579 @default.
• W3082087942 hasConceptScore W3082087942C2780145431 @default.
• W3082087942 hasConceptScore W3082087942C2780615674 @default.
• W3082087942 hasConceptScore W3082087942C512399662 @default.
• W3082087942 hasConceptScore W3082087942C54847362 @default.
• W3082087942 hasConceptScore W3082087942C71924100 @default.
• W3082087942 hasConceptScore W3082087942C84393581 @default.
• W3082087942 hasLocation W30820879421 @default.
• W3082087942 hasLocation W30820879422 @default.
• W3082087942 hasLocation W30820879423 @default.
• W3082087942 hasOpenAccess W3082087942 @default.
• W3082087942 hasPrimaryLocation W30820879421 @default.
• W3082087942 hasRelatedWork W1966087562 @default.
• W3082087942 hasRelatedWork W1967140159 @default.
• W3082087942 hasRelatedWork W2093460438 @default.
• W3082087942 hasRelatedWork W2181117567 @default.
• W3082087942 hasRelatedWork W2787612285 @default.
• W3082087942 hasRelatedWork W2883353278 @default.
• W3082087942 hasRelatedWork W2982630465 @default.
• W3082087942 hasRelatedWork W3156815556 @default.

• next